National Guideline Clearinghouse | Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion.

full-text ►
National Guideline Clearinghouse | Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion.


National Institute for Health and Care Excellence (NICE)

December 2, 2013

 

Guideline Title

Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion.

Bibliographic Source(s)

National Institute for Health and Care Excellence (NICE). Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion. London (UK): National Institute for Health and Care Excellence (NICE); 2013 May. 62 p. (Technology appraisal guidance; no. 283).

Guideline Status

This is the current release of the guideline.